Clinical Trial

A Phase 1 Clinical Trial of NTQ5082 in Healthy Volunteers

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 19, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
NTQ5082 capsule is a small molecule CFB factor inhibitor. The study is a randomized, double-blind, placebo-controlled, dose escalation phase 1 clinical trial to evaluate the safety, tolerability and PK/PD characteristics of NTQ5082 capsules orally administered in healthy subjects in single and multiple doses.
Trial Details
NCT Number NCT06560593
Lead Sponsor Nanjing Chia-tai Tianqing Pharmaceutical
Conditions Complement-mediated Hemolytic Diseases
Enrollment 82 participants
Start Date 2024-08
Primary Completion 2024-12 (estimated)
Study Completion 2025-02 (estimated)
Updated on ClinicalTrials.gov 2024-08-19